Your browser is no longer supported. Please, upgrade your browser.
CTIC CTI BioPharma Corp. weekly Stock Chart
CTIC [NASD]
CTI BioPharma Corp.
Index- P/E- EPS (ttm)-0.53 Insider Own0.10% Shs Outstand58.31M Perf Week-6.35%
Market Cap43.85M Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float57.69M Perf Month-0.53%
Income-31.00M PEG- EPS next Q-0.24 Inst Own48.40% Short Float0.35% Perf Quarter13.25%
Sales17.80M P/S2.46 EPS this Y57.60% Inst Trans0.50% Short Ratio1.91 Perf Half Y-10.49%
Book/sh0.55 P/B1.37 EPS next Y-24.40% ROA-42.70% Target Price4.00 Perf Year-56.02%
Cash/sh0.80 P/C0.94 EPS next 5Y- ROE-68.20% 52W Range0.60 - 1.76 Perf YTD2.51%
Dividend- P/FCF- EPS past 5Y34.50% ROI-45.20% 52W High-57.27% Beta1.62
Dividend %- Quick Ratio- Sales past 5Y-5.40% Gross Margin99.50% 52W Low25.31% ATR0.04
Employees46 Current Ratio1.80 Sales Q/Q109.10% Oper. Margin- RSI (14)38.02 Volatility4.66% 4.68%
OptionableYes Debt/Eq0.33 EPS Q/Q32.10% Profit Margin- Rel Volume1.03 Prev Close0.75
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume104.79K Price0.75
Recom2.00 SMA20-4.25% SMA50-5.95% SMA200-13.01% Volume0 Change0.00%
Mar-05-19Initiated Lake Street Buy $4
Mar-26-18Initiated Needham Buy $10
Mar-07-18Initiated JMP Securities Mkt Outperform $8
Sep-12-17Initiated Jefferies Buy $7.50
Feb-10-16Downgrade WallachBeth Hold → Sell
Feb-10-16Downgrade Piper Jaffray Overweight → Neutral
Feb-10-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-09-15Downgrade WallachBeth Buy → Hold $4.50 → $1.60
Aug-05-14Upgrade WallachBeth Hold → Buy $4.50
Mar-19-14Initiated WallachBeth Hold $4.50
Nov-04-13Initiated HC Wainwright Buy $4
Nov-06-19 09:08AM  CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting PR Newswire
Nov-04-19 04:05PM  CTI BioPharma Reports Third Quarter 2019 Financial Results PR Newswire
Oct-01-19 07:00AM  CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia PR Newswire
Aug-01-19 04:05PM  CTI BioPharma Reports Second Quarter 2019 Financial Results PR Newswire
Jul-18-19 07:00AM  CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis PR Newswire -5.09%
Jun-13-19 07:00AM  CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20 PR Newswire
May-29-19 07:00AM  CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5 PR Newswire
May-02-19 06:40PM  CTI BioPharma: 1Q Earnings Snapshot Associated Press
04:05PM  CTI BioPharma Reports First Quarter 2019 Financial Results PR Newswire
Apr-03-19 07:00AM  CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10 PR Newswire
Mar-13-19 05:33PM  CTI BioPharma: 4Q Earnings Snapshot Associated Press
04:05PM  CTI BioPharma Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights PR Newswire
Mar-12-19 07:00AM  CTI BioPharma to Present at Oppenheimer's 29th Annual Healthcare Conference on Tuesday, Mar. 19 PR Newswire +5.09%
Feb-25-19 05:52PM  CTI BioPharma ups CEO pay as stock hovers near record low American City Business Journals +6.57%
Feb-20-19 07:00AM  CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27 PR Newswire
Feb-13-19 12:22AM  CTI BioPharma collects $10M payment for former chemotherapy drug American City Business Journals
Feb-11-19 07:00AM  CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX® PR Newswire
Feb-08-19 06:25PM  Ex-CTI BioPharma CEO seeks startup funds as yacht lawsuit dismissed American City Business Journals -5.23%
Feb-01-19 07:01AM  CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update PR Newswire -15.97%
Dec-28-18 07:00AM  CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib PR Newswire
Dec-18-18 04:01PM  CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development PR Newswire
Dec-17-18 07:53PM  As CTI BioPharma restructures, former CEO James Bianco launches startup American City Business Journals
Dec-14-18 07:47AM  The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch Benzinga -8.46%
Dec-13-18 02:20PM  CTI BioPharma lays off half of workforce to save cash for lead drug trial American City Business Journals -8.11%
10:03AM  CTI BioPharma Announces Restructuring Plan PR Newswire
Nov-26-18 04:01PM  CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency PR Newswire
Nov-23-18 07:35AM  Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and Charles & Colvard What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-01-18 12:10PM  CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates Zacks
09:40AM  CTI BioPharma: 3Q Earnings Snapshot Associated Press
08:01AM  CTI BioPharma Reports Third Quarter 2018 Financial Results PR Newswire
Oct-25-18 07:01AM  CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018 PR Newswire
Oct-01-18 10:05AM  Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock? Zacks
07:01AM  CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review PR Newswire
Sep-26-18 07:01AM  CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3 PR Newswire
Sep-07-18 01:20PM  CTI BioPharma co-founder comes to his own defense in yacht repossession lawsuit American City Business Journals
Sep-06-18 05:50PM  CTI BioPharma co-founder and chief scientific officer leaves as stock sits near record low American City Business Journals
Aug-29-18 01:47PM  Sheriff's deputies can't find CTI BioPharma founder to serve him lawsuit over repossessed yacht American City Business Journals
Aug-02-18 02:30PM  CTI BioPharma Corp. to Host Earnings Call ACCESSWIRE
09:40AM  CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:36AM  CTI BioPharma: 2Q Earnings Snapshot Associated Press
08:00AM  CTI BioPharma Reports Second Quarter 2018 Financial Results PR Newswire
Jul-26-18 04:01PM  CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018 PR Newswire
Jul-19-18 11:14AM  CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA Zacks
09:14AM  Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals ACCESSWIRE
Jul-18-18 11:47AM  Why CTI BioPharma Corp. Crashed Today Motley Fool -43.36%
07:00AM  CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA PR Newswire
Jul-13-18 08:50AM  Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit Zacks
Jul-10-18 09:33AM  CTI BioPharma Falls After Failure of Pivotal Lymphoma Study Zacks
Jul-09-18 05:02PM  Why CTI BioPharma, PetMed Express, and Pfizer Slumped Today Motley Fool -13.85%
04:36PM  Groupon, JPMorgan Chase rise, Twitter, CTI BioPharma fall Associated Press
12:26PM  Why CTI BioPharma Corp. Is Sinking Today Motley Fool
07:58AM  UPDATE: CTI BioPharma stock slides 12% after failed trial of treatment for non-Hodgkin lymphoma MarketWatch
07:27AM  CTI Biopharma's cancer drug fails late-stage trial Reuters
07:06AM  CTI Biopharma's cancer treatment fails to meet trial goal Reuters
07:00AM  Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma PR Newswire
Jul-02-18 07:00AM  CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib PR Newswire +5.02%
Jun-30-18 05:32PM  The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus Benzinga
Jun-14-18 07:02AM  CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference PR Newswire
Jun-12-18 10:20AM  Analysts Expect Breakeven For CTI BioPharma Corp (NASDAQ:CTIC) Simply Wall St.
Jun-06-18 07:01AM  CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-03-18 05:36PM  CTI BioPharma: 1Q Earnings Snapshot Associated Press
04:01PM  CTI BioPharma Reports First Quarter 2018 Financial Results PR Newswire
May-02-18 04:42PM  CTI BioPharma Corp (NASDAQ:CTIC) Is Trading At A 22% Discount Simply Wall St.
Apr-26-18 04:05PM  CTI BioPharma to Report First Quarter 2018 Financial Results on May 3, 2018 PR Newswire
Apr-25-18 04:02PM  Does CTI BioPharma Corps (NASDAQ:CTIC) Latest Financial Perfomance Look Strong? Simply Wall St.
Apr-18-18 03:57PM  What Should You Know About CTI BioPharma Corps (NASDAQ:CTIC) Earnings Trajectory? Simply Wall St.
Mar-13-18 07:40AM  Wired News CTI BioPharmas Pacritinib Phase-3 PERSIST-2 Clinical Trial Data Published in JAMA Oncology ACCESSWIRE
Mar-09-18 07:05AM  CTI BioPharma to Present at Upcoming Investor Conferences PR Newswire
07:00AM  CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology PR Newswire
Mar-07-18 04:27PM  CTI BioPharma reports 4Q loss Associated Press
04:01PM  CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
01:15PM  CTI BioPharma Corp (NASDAQ:CTIC): What Does It Mean For Your Portfolio? Simply Wall St.
12:30PM  CTI BioPharma Corp. to Host Earnings Call ACCESSWIRE
Feb-28-18 11:07AM  When Will CTI BioPharma Corp (NASDAQ:CTIC) Breakeven? Simply Wall St.
08:00AM  CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018 PR Newswire
Feb-14-18 04:05PM  CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference PR Newswire +6.63%
Feb-13-18 07:00AM  CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock PR Newswire
Feb-09-18 07:00AM  CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock PR Newswire +6.64%
Feb-05-18 07:55AM  CTI BioPharma Announces Launch of Follow-On Offering PR Newswire
Jan-29-18 05:02PM  Who Owns CTI BioPharma Corp (NASDAQ:CTIC)? Simply Wall St.
Jan-25-18 04:40PM  CTI BioPharma Provides Corporate and European Regulatory Update PR Newswire
Jan-23-18 03:39PM  How Is Novartiss Kymriah Positioned for 2018? Market Realist
Jan-18-18 01:30AM  CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX® PR Newswire
Jan-10-18 10:12AM  What Are Analysts Saying About CTI BioPharma Corps (NASDAQ:CTIC) Earnings Trend? Simply Wall St.
Jan-01-18 11:31AM  ETFs with exposure to CTI BioPharma Corp. : January 1, 2018 Capital Cube
Dec-22-17 09:25AM  CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017 Capital Cube
Dec-21-17 11:23AM  ETFs with exposure to CTI BioPharma Corp. : December 21, 2017 Capital Cube
09:06AM  Edited Transcript of CTIC earnings conference call or presentation 6-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Dec-15-17 11:25AM  Does CTI BioPharma Corps (NASDAQ:CTIC) Past Performance Indicate A Stronger Future? Simply Wall St.
Nov-20-17 11:45AM  Is CTI BioPharma Corp (CTIC) Undervalued? Simply Wall St.
Nov-10-17 12:08PM  ETFs with exposure to CTI BioPharma Corp. : November 10, 2017 Capital Cube
Nov-08-17 01:30AM  CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference PR Newswire
Nov-06-17 04:47PM  CTI BioPharma reports 3Q loss Associated Press
04:01PM  CTI BioPharma Reports Third Quarter 2017 Financial Results PR Newswire
07:20AM  CTI BioPharma Corp. to Host Earnings Call ACCESSWIRE
Oct-30-17 01:30AM  CTI BioPharma to Report Third Quarter 2017 Financial Results on November 6, 2017 PR Newswire
Oct-26-17 10:25AM  ETFs with exposure to CTI BioPharma Corp. : October 26, 2017 Capital Cube
Oct-16-17 09:50AM  ETFs with exposure to CTI BioPharma Corp. : October 16, 2017 Capital Cube
Oct-02-17 10:47AM  ETFs with exposure to CTI BioPharma Corp. : October 2, 2017 Capital Cube
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.